Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer

Iván Prieto-Potin, Clara Montagut, Beatriz Bellosillo, Matthew Evans, Matthew Smith, Linea Melchior, Werner Reiltin, Michael Bennett, Veronica Pennati, Francesca Castiglione, Karl Friedrich Bürrig, Ulrike Cooper, Barbara Dockhorn-Dworniczak, Christiana Rossenbach, Claudia M. Luna-Aguirre, Hugo A. Barrera-Saldaña, José C. Machado, José L. Costa, Rinat Yacobi, Hilla Tabibian-KeissarSimonetta Buglioni, Livia Ronchetti, Lotte Douglas-Berger, Hendrikus J. Dubbink, Mohammed Alorini, Jean Christophe Sabourin, Federico Rojo

Research output: Contribution to journalArticle

Abstract

Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal growth factor receptor requires the assessment of the mutational status of exons 2, 3, and 4 of the NRAS and KRAS oncogenes. Moreover, the mutational status of exon 15 of the BRAF oncogene is a marker of poor prognosis in CRC. The Idylla NRAS-BRAF Mutation Test is a reliable, simple (<2 minutes hands-on time), and quick (<2 hours turnaround time) sample-to-result solution, enabling the detection of clinically relevant mutations in NRAS (18 mutations) and BRAF (5 mutations). A multicenter study was conducted in 14 centers using the Idylla NRAS-BRAF Mutation Test to assess the NRAS and BRAF mutational status of 418 formalin-fixed, paraffin-embedded tissue samples from CRC patients. Results were compared with those obtained earlier by routine reference methods, including next-generation sequencing, pyrosequencing, mass spectrometry–based assays, PCR-based assays, and Sanger sequencing. In case of discordance, additional tests were performed by digital droplet PCR. Overall, after testing confirmation and excluding invalids/errors by design, concordances between the Idylla NRAS-BRAF Mutation Test and the reference test results were found in almost perfect agreement. In conclusion, the Idylla NRAS-BRAF Mutation Test enables the routine detection of all NRAS and BRAF mutations deemed clinically relevant according to the latest clinical guidelines, without necessitating molecular expertise or infrastructure.

Original languageEnglish
Pages (from-to)664-676
Number of pages13
JournalJournal of Molecular Diagnostics
Volume20
Issue number5
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Colorectal Neoplasms
Mutation
Oncogenes
Exons
Polymerase Chain Reaction
Epidermal Growth Factor Receptor
Paraffin
Formaldehyde
Multicenter Studies
Monoclonal Antibodies
Guidelines

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Cite this

Prieto-Potin, I., Montagut, C., Bellosillo, B., Evans, M., Smith, M., Melchior, L., ... Rojo, F. (2018). Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. Journal of Molecular Diagnostics, 20(5), 664-676. https://doi.org/10.1016/j.jmoldx.2018.05.008

Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. / Prieto-Potin, Iván; Montagut, Clara; Bellosillo, Beatriz; Evans, Matthew; Smith, Matthew; Melchior, Linea; Reiltin, Werner; Bennett, Michael; Pennati, Veronica; Castiglione, Francesca; Bürrig, Karl Friedrich; Cooper, Ulrike; Dockhorn-Dworniczak, Barbara; Rossenbach, Christiana; Luna-Aguirre, Claudia M.; Barrera-Saldaña, Hugo A.; Machado, José C.; Costa, José L.; Yacobi, Rinat; Tabibian-Keissar, Hilla; Buglioni, Simonetta; Ronchetti, Livia; Douglas-Berger, Lotte; Dubbink, Hendrikus J.; Alorini, Mohammed; Sabourin, Jean Christophe; Rojo, Federico.

In: Journal of Molecular Diagnostics, Vol. 20, No. 5, 01.09.2018, p. 664-676.

Research output: Contribution to journalArticle

Prieto-Potin, I, Montagut, C, Bellosillo, B, Evans, M, Smith, M, Melchior, L, Reiltin, W, Bennett, M, Pennati, V, Castiglione, F, Bürrig, KF, Cooper, U, Dockhorn-Dworniczak, B, Rossenbach, C, Luna-Aguirre, CM, Barrera-Saldaña, HA, Machado, JC, Costa, JL, Yacobi, R, Tabibian-Keissar, H, Buglioni, S, Ronchetti, L, Douglas-Berger, L, Dubbink, HJ, Alorini, M, Sabourin, JC & Rojo, F 2018, 'Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer', Journal of Molecular Diagnostics, vol. 20, no. 5, pp. 664-676. https://doi.org/10.1016/j.jmoldx.2018.05.008
Prieto-Potin, Iván ; Montagut, Clara ; Bellosillo, Beatriz ; Evans, Matthew ; Smith, Matthew ; Melchior, Linea ; Reiltin, Werner ; Bennett, Michael ; Pennati, Veronica ; Castiglione, Francesca ; Bürrig, Karl Friedrich ; Cooper, Ulrike ; Dockhorn-Dworniczak, Barbara ; Rossenbach, Christiana ; Luna-Aguirre, Claudia M. ; Barrera-Saldaña, Hugo A. ; Machado, José C. ; Costa, José L. ; Yacobi, Rinat ; Tabibian-Keissar, Hilla ; Buglioni, Simonetta ; Ronchetti, Livia ; Douglas-Berger, Lotte ; Dubbink, Hendrikus J. ; Alorini, Mohammed ; Sabourin, Jean Christophe ; Rojo, Federico. / Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. In: Journal of Molecular Diagnostics. 2018 ; Vol. 20, No. 5. pp. 664-676.
@article{df258264b33f44dfa6171c380f5b492d,
title = "Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer",
abstract = "Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal growth factor receptor requires the assessment of the mutational status of exons 2, 3, and 4 of the NRAS and KRAS oncogenes. Moreover, the mutational status of exon 15 of the BRAF oncogene is a marker of poor prognosis in CRC. The Idylla NRAS-BRAF Mutation Test is a reliable, simple (<2 minutes hands-on time), and quick (<2 hours turnaround time) sample-to-result solution, enabling the detection of clinically relevant mutations in NRAS (18 mutations) and BRAF (5 mutations). A multicenter study was conducted in 14 centers using the Idylla NRAS-BRAF Mutation Test to assess the NRAS and BRAF mutational status of 418 formalin-fixed, paraffin-embedded tissue samples from CRC patients. Results were compared with those obtained earlier by routine reference methods, including next-generation sequencing, pyrosequencing, mass spectrometry–based assays, PCR-based assays, and Sanger sequencing. In case of discordance, additional tests were performed by digital droplet PCR. Overall, after testing confirmation and excluding invalids/errors by design, concordances between the Idylla NRAS-BRAF Mutation Test and the reference test results were found in almost perfect agreement. In conclusion, the Idylla NRAS-BRAF Mutation Test enables the routine detection of all NRAS and BRAF mutations deemed clinically relevant according to the latest clinical guidelines, without necessitating molecular expertise or infrastructure.",
author = "Iv{\'a}n Prieto-Potin and Clara Montagut and Beatriz Bellosillo and Matthew Evans and Matthew Smith and Linea Melchior and Werner Reiltin and Michael Bennett and Veronica Pennati and Francesca Castiglione and B{\"u}rrig, {Karl Friedrich} and Ulrike Cooper and Barbara Dockhorn-Dworniczak and Christiana Rossenbach and Luna-Aguirre, {Claudia M.} and Barrera-Salda{\~n}a, {Hugo A.} and Machado, {Jos{\'e} C.} and Costa, {Jos{\'e} L.} and Rinat Yacobi and Hilla Tabibian-Keissar and Simonetta Buglioni and Livia Ronchetti and Lotte Douglas-Berger and Dubbink, {Hendrikus J.} and Mohammed Alorini and Sabourin, {Jean Christophe} and Federico Rojo",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.jmoldx.2018.05.008",
language = "English",
volume = "20",
pages = "664--676",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "5",

}

TY - JOUR

T1 - Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer

AU - Prieto-Potin, Iván

AU - Montagut, Clara

AU - Bellosillo, Beatriz

AU - Evans, Matthew

AU - Smith, Matthew

AU - Melchior, Linea

AU - Reiltin, Werner

AU - Bennett, Michael

AU - Pennati, Veronica

AU - Castiglione, Francesca

AU - Bürrig, Karl Friedrich

AU - Cooper, Ulrike

AU - Dockhorn-Dworniczak, Barbara

AU - Rossenbach, Christiana

AU - Luna-Aguirre, Claudia M.

AU - Barrera-Saldaña, Hugo A.

AU - Machado, José C.

AU - Costa, José L.

AU - Yacobi, Rinat

AU - Tabibian-Keissar, Hilla

AU - Buglioni, Simonetta

AU - Ronchetti, Livia

AU - Douglas-Berger, Lotte

AU - Dubbink, Hendrikus J.

AU - Alorini, Mohammed

AU - Sabourin, Jean Christophe

AU - Rojo, Federico

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal growth factor receptor requires the assessment of the mutational status of exons 2, 3, and 4 of the NRAS and KRAS oncogenes. Moreover, the mutational status of exon 15 of the BRAF oncogene is a marker of poor prognosis in CRC. The Idylla NRAS-BRAF Mutation Test is a reliable, simple (<2 minutes hands-on time), and quick (<2 hours turnaround time) sample-to-result solution, enabling the detection of clinically relevant mutations in NRAS (18 mutations) and BRAF (5 mutations). A multicenter study was conducted in 14 centers using the Idylla NRAS-BRAF Mutation Test to assess the NRAS and BRAF mutational status of 418 formalin-fixed, paraffin-embedded tissue samples from CRC patients. Results were compared with those obtained earlier by routine reference methods, including next-generation sequencing, pyrosequencing, mass spectrometry–based assays, PCR-based assays, and Sanger sequencing. In case of discordance, additional tests were performed by digital droplet PCR. Overall, after testing confirmation and excluding invalids/errors by design, concordances between the Idylla NRAS-BRAF Mutation Test and the reference test results were found in almost perfect agreement. In conclusion, the Idylla NRAS-BRAF Mutation Test enables the routine detection of all NRAS and BRAF mutations deemed clinically relevant according to the latest clinical guidelines, without necessitating molecular expertise or infrastructure.

AB - Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal growth factor receptor requires the assessment of the mutational status of exons 2, 3, and 4 of the NRAS and KRAS oncogenes. Moreover, the mutational status of exon 15 of the BRAF oncogene is a marker of poor prognosis in CRC. The Idylla NRAS-BRAF Mutation Test is a reliable, simple (<2 minutes hands-on time), and quick (<2 hours turnaround time) sample-to-result solution, enabling the detection of clinically relevant mutations in NRAS (18 mutations) and BRAF (5 mutations). A multicenter study was conducted in 14 centers using the Idylla NRAS-BRAF Mutation Test to assess the NRAS and BRAF mutational status of 418 formalin-fixed, paraffin-embedded tissue samples from CRC patients. Results were compared with those obtained earlier by routine reference methods, including next-generation sequencing, pyrosequencing, mass spectrometry–based assays, PCR-based assays, and Sanger sequencing. In case of discordance, additional tests were performed by digital droplet PCR. Overall, after testing confirmation and excluding invalids/errors by design, concordances between the Idylla NRAS-BRAF Mutation Test and the reference test results were found in almost perfect agreement. In conclusion, the Idylla NRAS-BRAF Mutation Test enables the routine detection of all NRAS and BRAF mutations deemed clinically relevant according to the latest clinical guidelines, without necessitating molecular expertise or infrastructure.

UR - http://www.scopus.com/inward/record.url?scp=85051652688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051652688&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2018.05.008

DO - 10.1016/j.jmoldx.2018.05.008

M3 - Article

AN - SCOPUS:85051652688

VL - 20

SP - 664

EP - 676

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 5

ER -